Getinge Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Getinge (STO:GETI B) Full Year 2024 Results

Key Financial Results

• Revenue: kr34.8b (up 9.2% from FY 2023).
• Net income: kr1.64b (down 32% from FY 2023).
• Profit margin: 4.7% (down from 7.6% in FY 2023).
• EPS: kr6.01 (down from kr8.86 in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Getinge Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 19%.

The primary driver behind last 12 months revenue was the Acute Care Therapies segment contributing a total revenue of kr17.9b (52% of total revenue). Notably, cost of sales worth kr18.6b amounted to 54% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to kr5.98b (41% of total expenses). Explore how GETI B's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Getinge.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.